EU/3/10/742

Table of contents

About

On 10 June 2010, orphan designation (EU/3/10/742) was granted by the European Commission to Aprea AB, Sweden, for 2-methoxymethyl-2-hydroxymethyl-1-azabicyclo[2,2,2]octan-3-one (also known as APR-246) for the treatment of acute myeloid leukaemia.

In March 2017, Aprea AB changed name to Aprea Therapeutics AB.

The sponsor’s address was updated in October 2020.

Key facts

Active substance
2-Methoxymethyl-2-hydroxymethyl-1-azabicyclo[2,2,2]octan-3-one
Disease / condition
Treatment of acute myeloid leukaemia
Date of first decision
10/06/2010
Outcome
Positive
EU designation number
EU/3/10/742

Sponsor's contact details

Aprea Therapeutics AB
Nobels väg 16
171 65 Solna
Sweden
Tel: +46 (0)8 524 861 82
E-mail: info@aprea.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating